《Table 1 Demographic and patient-referred data》
提示:宽带有限、当前游客访问压缩模式
本系列图表出处文件名:随高清版一同展现
《Safety of intrathecal injection of Wharton's jellyderived mesenchymal stem cells in amyotrophic lateral sclerosis therapy》
WJ-MSC:Wharton’s jelly-derived mesenchymal stem cells.
Forty-three patients,consisting of 16 females and 27males,aged 57.3 years,were included in the final analysis.The mean weight of patients was 75.35 kg at the beginning of the therapy.The mean dose of WJ-MSC in one intrathecal injection was 0.42×106 cells/kg(Table 1).All patients were treated with riluzole 100 mg in 2 doses per day.
图表编号 | XD0040608700 严禁用于非法目的 |
---|---|
绘制时间 | 2019.02.01 |
作者 | Monika Barczewska、Mariusz Grudniak、Stanisaw Maksymowicz、Tomasz Siwek、Tomasz Odak、Katarzyna Jezierska-Woniak、Dominika Gadysz、Wojciech Maksymowicz |
绘制单位 | Department of Neurology and Neurosurgery, School of Medicine, Collegium Medicum-University of Warmia and Mazury in Olsztyn、University Clinical Hospital in Olsztyn、Instytut Terapii Komórkowych w Olsztynie(Cell Therapies Institute, FamiCord Group)、Polski Ba |
更多格式 | 高清、无水印(增值服务) |